Drug Repurposing Service Providers Market, 2020-2030

Drug Repurposing Service Providers Market, 2020-2030

Novel drug / therapy development is a complex and capital intensive process characterized by several challenges and setbacks. A prominent concern reported by innovators is attrition (close to 90%) of candidate drugs / therapies owing to various reasons, in addition to therapeutic efficacy and safety. Moreover, it is estimated that a new drug takes anywhere between 10-12 years to progress from the bench to market. Given the increasing global population and rising incidence of various types of diseases, medical researchers and drug developers are faced with a growing need to expedite time-to-market for their respective therapeutic candidates, while optimizing the R&D expenditure. Of late, the repurposing of marketed / shelved / pipeline candidates for the treatment of diseases different from what they were originally developed for, has emerged as a viable business strategy. The rising popularity of this approach may be attributed to benefits, such as reduced development timelines and relatively higher success rates (considering that the safety profiles of such candidates have already been established). In fact, of 28 drugs (including both novel and repurposed) approved by the USFDA in the first quarter of 2020, 12 were repurposed. Further, it is estimated that around 25%-40% of annual pharmaceutical revenues are generated from the sales of repurposed drugs. It is also worth highlighting that repurposing offers significant cost saving opportunities to innovators, while guaranteeing substantial returns on investment. In fact, the cost of developing and marketing a repurposed drug has been estimated to be USD 300 million, compared to the USD 2-3 billion investment required to bring a novel drug into the market. In this context, it is worth mentioning that several drugs (150+) that are presently being used / evaluated to treat COVID-19 are repurposed; prominent examples include chloroquine / hydroxychloroquine (anti-malarial drug) and remdesivir (initially developed to treat hepatitis C).

A number of service providers, including contract research organizations (CROs), claim to provide the necessary support to drug developers in identifying / predicting prospective Clinical Trials for repurposing. Such companies offer a variety of services, encompassing both drug discovery operations and consultancy requirements. In fact, many such players claim to have developed proprietary platforms based on advanced technologies, such as big data analysis, artificial intelligence (AI) and real-world evidence, in order to facilitate drug repurposing related decision-making. This upcoming industry has witnessed significant partnership activity in the last ten years, with service providers having established strategic collaborations with innovator companies, as well as information technology (IT) and data management experts. In future, experts believe that outsourcing activity related to drug repurposing is anticipated to grow at a rate of 20-25%.

SCOPE OF THE REPORT

The ‘‘Drug Repurposing Service Providers Market, 2020-2030’’ report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. The study also includes an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. Amongst other elements, the report includes:
A detailed assessment of the current market landscape of companies offering drug repurposing services based on several relevant parameters, including year of establishment, company size, location of headquarters, type of company, type of service offered (drug discovery, consulting and others), purpose of repurposing, type of repurposing and technology platform used.
A detailed analysis of the various partnerships that have been signed within this domain, during the period 2013-2020, along with information on year of partnership, type of partnership, and partner company, type of technology / platform used, and key value drivers (such as target therapeutic area and type of drug molecule) and location of collaborators.
A review of recent initiatives undertaken by big pharma players across the globe for the discovery and development of repurposed drugs, along with information on number of initiatives, year of initiative. It also features a benchmark analysis of top 11 big pharma players (in terms of annual revenues of 2019), comparing them across various relevant parameters, such as name of repurposed drug, drug class, target therapeutic area, phase of development and target patient population.
A detailed analysis of terminated / withdrawn / suspended drug candidates that can be repurposed, based on several relevant parameters, such as current recruitment status, trial phase, cause of discontinuation of trial, type of sponsor, target therapeutic area(s).
A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.
Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs. Each profile features an overview of the company (including information on its year of establishment, company size and location of headquarters), details on type of technology platform used, drug discovery and repurposing focused service portfolio, and an informed future outlook.
Detailed profiles of key organizations; each profile features an overview of the company (including information on year of establishment, location of headquarters, network affiliates and type of service offered), and recent developments related to drug repurposing. It provides brief discussion on the various research institutions and non-profit organizations that are presently engaged in the drug repurposing domain.
An elaborate discussion on the future opportunities / trends within the drug repurposing service provider outsourcing market that are likely to influence the growth of this domain over the coming years.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the drug repurposing service providers market. Based on various important parameters, such as projected rise in the overall pharmaceutical R&D expenditure, drug discovery costs, and outsourcing profile, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of repurposing approach (disease centric, target-centric and drug-centric), [B] therapeutic area (same therapeutic area and different therapeutic area), [C] type of drug molecule (biologic and small molecule), and [D] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. In addition, the report discusses the impact of the recent COVID-19 pandemic on the global drug repurposing service providers market, along with providing details related to the future market opportunity for players engaged in this domain.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. All actual figures have been sourced and analyzed from publicly available information forums and inputs from primary research. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming decade, the report also provides our independent view on various emerging trends in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market, gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Who are the leading players offering drug repurposing services?
What kind of initiatives have been undertaken by big pharma players related to drug repurposing?
What kind of partnership models are most commonly adopted by stakeholders in this industry?
What is the role of non-profit organizations and academic players in this domain?
What are the potential cost benefits of drug repurposing, compared to the traditional drug development process?
What factors are likely to influence the evolution of this upcoming market?
How has the recent COVID-19 pandemic likely impacted the demand for drug repurposing?
How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the drug repurposing service providers market and its likely evolution in the short-mid and long terms.

Chapter 3 provides a brief introduction to drug repurposing, highlighting key historical and development milestones. It also provides a general overview of the strategies / approaches used for drug repurposing, featuring a discussion on the three commonly used methodologies in this domain. Further, the chapter presents details related to the various steps involved in repurposing of a drug and its comparison to the traditional de novo drug development process. It further highlights the role of service providers that operate within the drug repurposing market and the different types of services they usually offer. In addition, the chapter includes the advantages and challenges associated with drug repurposing, along with the key parameters that need to be considered while selecting a service provider.

Chapter 4 provides a detailed review of the current market landscape of companies offering drug repurposing services based on several relevant parameters, including year of establishment, company size, location of headquarters, type of company, type of service offered (drug discovery, consulting services and others), purpose of repurposing, type of repurposing and technology platform used.

Chapter 5 features elaborate profiles of key organizations featuring an overview of the company, including information on year of establishment, location of headquarters, network affiliates and type of service offered along with, recent developments made by the organizations. It provides information on the various research institutions and non-profit organizations that are involved in drug repurposing industry.

Chapter 6 features detailed profiles of key players that specialize in offering services for the development of repurposed drugs. Each profile features an overview of the company, along with information on its year of establishment, number of employees, location of headquarters, details related to type of technology platform used, drug discovery and repurposing focused service portfolio, and an informed future outlook.

Chapter 7 features a detailed analysis of the various partnerships that have taken place in this domain, highlighting the trend in the number of companies that have entered into collaborations between 2013-2020. Further, the analysis takes into account several relevant parameters, such as year of partnership, type of partnership, partner company, type of technology / platform used by the service provider, and other key value drivers (including target therapeutic area and geographical location of the service provider). Moreover, it presents a schematic world map representation highlighting the geographical distribution of the partnership activity within this domain, as well as presenting both inter- and intracontinental deals.

Chapter 8 presents a review of recent initiatives undertaken by big pharma players across the world for the discovery and development of repurposed drugs, highlighting trends across various parameters, such as number of initiatives, year of initiative, and benchmark analysis of big pharma players. The analysis allows companies to feature a detailed version on their existing capabilities, including name of the repurposed drug, drug class, target therapeutic area, phase of development and target patient population.

Chapter 9 presents a detailed analysis of terminated / withdrawn / suspended clinical drug development programs (identified using clinical trials) that have the potential to be repurposed, based on various relevant parameters, such as trial recruitment status, reason for withdrawal, termination and suspension of the trial, trial phase, type of sponsor and target therapeutic area(s).

Chapter 10 features a detailed analysis on the cost savings enable by use of the drug repurposing approach, by comparing it with the traditional de novo development process.

Chapter 11 presents a detailed market forecast analysis, highlighting the likely growth of drug repurposing service providers market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of repurposing approaches (disease centric approach, target-centric approach and drug-centric approach, [B] therapeutic area (same therapeutic area and different therapeutic area), [C] type of drug molecule (biologics and small molecules), and [D] geography (North America, Europe and Asia-Pacific).

Chapter 12 highlights the effect of coronavirus outbreak on the global pharmaceutical industry. It includes a brief discussion on the short-term and long-term impact of COVID-19 upsurge on the supply chain and market opportunity for service providers. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 13 highlights an elaborate discussion on the future opportunities / trends for the drug repurposing service providers outsourcing market that are likely to influence the growth of this domain over the coming years.

Chapter 14 is a collection of interview transcript(s) of the discussions held with key stakeholders in the industry.

Chapter 15 is an appendix that provides the list of potential drug-indication candidates for drug repurposing that have been terminated / withdrawn / suspended in clinical trials.

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES / LIST OF COMPANIES AND ORGANIZATIONS

1. 3BIGS
2. IIT Kharagpur
3. AbbVie
4. Abiomics Europe
5. Actto Pharma
6. AI VIVO
7. Alzheimer's Drug Discovery Foundation
8. Ampel Biosolutions
9. Anaxomics
10. Anticancer Fund
11. Apodd
12. Ariel University
13. Astellas Pharma
14. AstraZeneca
15. Auxilis Pharma
16. Avivia
17. Bayer
18. BayPoint Biosystems
19. BenevolentAI
20. Bill & Melinda Gates
21. Biovista
22. Bioxcel
23. BioXplor
24. Boehringer Ingelheim
25. Bright Focus Foundation
26. California Institute of Medical Science
27. Cambridge Judge Business School
28. Cancer Research UK
29. Cardiomedex
30. Carnegie Mellon University
31. ChemBio Discovery Solutions
32. Chordoma Foundation
33. Cloud Pharm
34. Columbia University
35. Creative Biolabs
36. Cresset
37. CSIR
38. Cures within Reach
39. Cyclica
40. Dabur
41. Dana Farber Cancer Institute
42. Delta 4
43. Drugs for Neglected Diseases and Initiative
44. DTU - Technical University of Denmark
45. eBioStat
46. ecancer
47. Eli Lilly
48. Empiric Logic
49. espeRare
50. Euretos
51. Eurofins
52. Evotec
53. Excelra
54. FindaCure
55. Fios Genomics
56. Fraxa
57. Galactica Biotech
58. Garvan Institute of Medical Research
59. Genome Biologics
60. Gilead Sciences
61. GlobalCures
62. Green Pharma
63. GSK
64. GVK BIO
65. Harrington Discovery Institute
66. Hartwig Medical Foundation
67. Healx
68. Helomics
69. Hybrigenics Services
70. IBM
71. Innoplexus
72. Innovate UK
73. Insiliance
74. Intomics
75. Iris Pharma
76. Jeeva Informatics
77. Johns Hopkins University
78. Keio University
79. Lantern Pharma
80. LEA
81. Linguamatics
82. Massachusetts Institute of Technology
83. McGill University
84. Melior Discovery
85. MicroMatrices
86. Milken Institute
87. Mind The Byte
88. Moebius Research
89. Moleculomics
90. Molsoft
91. Montreal Heart Institute
92. Mount Sinai
93. Myelin Repair Foundation
94. National Centre for Advancing Translational Sciences
95. National Institute of Pharmaceutical Education and Research
96. National University of La Plata
97. Netramark
98. Neuroproof
99. NeuroTheryX
100. Newcastle University
101. Nostrium biodiscovery
102. NovaData
103. Novalead Pharma
104. Novartis
105. Numedii
106. Panxome
107. Passport Technologies
108. Perlara
109. Pharmacelera
110. Pharnext
111. Physiogenex
112. PKD
113. Plebiotic
114. Protavio
115. Purdue University
116. Purposeful
117. Qrativ
118. RASA Life Science Informatics
119. Recursion Pharmaceuticals
120. Rediscovery Life Sciences
121. Reinvent Pharma
122. Robert Wood Johnson Foundation
123. Roche
124. Safan Bioinformatics
125. Sanofi
126. Selleck Chemical
127. Shake it up
128. Signia Therapuetics
129. Sistemic
130. Smart Pharma
131. SmartLigs
132. Socium
133. SOM Biotech
134. Stagen
135. Standigm
136. Syngene
137. SystaMedic
138. The Biogerontology Research Foundation
139. The Center for World Health & Medicine (CWHM)
140. The Cure Parkinson's Trust
141. The Michael J. Fox Foundation
142. The Scripps Research Institute
143. The University of Edinburgh
144. The University of New Mexico School of Medicine
145. The University of Queensland
146. The University of Texas Health Science Center
147. Therametrics
148. Therasis
149. Tovem
150. TranScientae
151. Transmed
152. University College London
153. University of California
154. University of Chicago
155. University of Colorado Boulder
156. University of Florida College of Medicine
157. University of Michigan
158. University of Pennsylvania
159. University of Wisconsin
160. Vector Institute
161. WIPO Re:Search


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Repurposing
3.2.1 History of Drug Repurposing
3.2.2 Strategies for Drug Repurposing
3.3. Repurposing versus the Traditional Drug Discovery
3.4. Benefits and Challenges Associated with Drug Repurposing
3.5. Drug Repurposing Service Providers
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Technology Specifications
4.2.6. Analysis by Type of Drug Molecule
4.2.7. Analysis by Status of Drug
4.2.8. Analysis by Repurposing Approach
4.2.9. Analysis by Services Offered
4.3. Drug Repurposing Service Provider: Overall Market Landscape of Big Data / Analytics Service Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Company Size and Location of Headquarters
4.3.5. Analysis by Technology Specifications
4.3.6. Analysis by Type of Drug Molecule
4.3.7. Analysis by Status of Drug
4.3.8. Analysis by Repurposing Approach
4.3.9. Analysis by Services Offered
4.4. Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Analysis by Technology Specifications
4.4.6. Analysis by Type of Drug Molecule
4.4.7. Analysis by Status of Drug
4.4.8. Analysis by Repurposing Approach
4.2.9. Analysis by Services Offered
5. ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS
5.1. Chapter Overview
5.2. Drug Repurposing Service Providers: List of Non-Profit Organizations
5.3. Stakeholder Profiles
5.3.1. Cures Within Reach
5.3.2. GlobalCures
5.3.3. Anticancer Fund
5.3.4. National Center for Advancing Translational Sciences
5.4. Drug Repurposing Service Providers: List of Academic Organizations
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Company Profiles for CROs
6.2.1 Auxiliis Pharma
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Future Outlook
6.2.2. ChemBio Discovery Solutions
6. 2.2.1. Company Overview
6. 2.2.2. Service Portfolio
6. 2.2.3. Future Outlook
6.2.3. GVK BIO
6.2.3.1. Company Overview
6.2.3.2. Technology Overview
6.2.3.3. Service Portfolio
6.2.3.4. Future Outlook
6.2.4. Iris Pharma
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Future Outlook
6.2.5. Physiogenex
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Future Outlook
6.3. Company Profiles for Big Data / Analytics Service Providers
6.3.1. Excelra
6.3.1.1. Company Overview
6.3.1.2. Technology Overview
6.3.1.3. Service Portfolio
6.3.1.4. Future Outlook
6.3.2. Smart Pharma
6.3.2.1. Company Overview
6.3.2.2. Technology Overview
6.3.2.3. Service Portfolio
6.3.2.4. Future Outlook
6.4. Company Profiles for Technology Providers
6.4.1. Lantern Pharma
6.4.1.1. Company Overview
6.4.1.2. Technology Overview
6.4.1.3. Service Portfolio
6.4.1.4. Future Outlook
6.4.2. Panxome
6.4.2.1. Company Overview
6.4.2.2. Technology Overview
6.4.2.3. Service Portfolio
6.4.2.4. Future Outlook
6.4.3. Pharmacelera
6.4.3.1. Company Overview
6.4.3.2. Technology Overview
6.4.3.3. Service Portfolio
6.4.3.4. Future Outlook
6.4.4. Socium
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Future Outlook
6.4.5. SOM Biotech
6.4.5.1. Company Overview
6.4.5.2. Technology Overview
6.4.5.3. Service Portfolio
6.4.5.4. Future Outlook
7. PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Drug Repurposing Service Providers: List of Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Type of Technology / Platform Used
7.3.5. Analysis by Therapeutic Area
7.3.6. Geographical Analysis
7.3.6.1. Continent-wise Distribution
7.3.6.2. Country-wise Distribution
8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. List of Drug Repurposing Initiatives of Big Pharma Players
8.2.1. Analysis by Number of Initiatives
8.2.2. Analysis by Year of Initiative
8.2.3. Analysis by Type of Initiative
8.2.4. Analysis by Therapeutic Area
8.2.5. Analysis by Type of Drug Molecule
8.2.6. Big Pharma Activity: Analysis by Year of Initiative and Company
8.2.7. Big Pharma Activity: Analysis by Type of Drug Molecule and Company
8.3. Competitive Benchmarking of Big Pharma Players
8.3.1. Big Pharma Investment Summary
8.4. Initiatives Undertaken by Leading Players
8.4.1. Initiatives Undertaken by AbbVie
8.4.1.1In-House Initiatives
8.4.2. Initiatives Undertaken by Astellas Pharma
8.4.2.1. Initiatives in Collaboration with Other Stakeholders
8.4.2.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.3. Initiatives Undertaken By AstraZeneca
8.4.3.1. In-House Initiatives
8.4.3.2 Initiatives in Collaboration with Other Stakeholders
8.4.4. Initiatives Undertaken by Bayer
8.4.4.1. Initiatives in Collaboration with Other Stakeholders
8.4.5. Initiatives Undertaken by Boehringer Ingelheim
8.4.5.1. Initiatives in Collaboration with Other Stakeholders
8.4.5.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.6. Initiatives Undertaken by Eli Lilly
8.4.6.1. Initiatives in Collaboration with Other Stakeholders
8.4.6.2 Recent Regulatory Approvals of Repurposed Drugs
8.4.7. Initiatives Undertaken by Gilead Sciences
8.4.7.1 Recent Regulatory Approvals of Repurposed Drugs
8.4.8. Initiatives Undertaken by GSK
8.4.8.1. In-House Initiatives
8.4.8.2 Initiatives in Collaboration with Other Stakeholders
8.4.9. Initiatives Undertaken by Novartis
8.4.9.1. In-House Initiatives
8.4.9.2 Initiatives in Collaboration with Other Stakeholders
8.4.9.3 Recent Regulatory Approvals of Repurposed Drugs
8.4.10. Initiatives Undertaken by Roche
8.4.10.1. In-House Initiatives
8.4.10.2 Initiatives in Collaboration with Other Stakeholders
8.4.11. Initiatives Undertaken by Sanofi
8.4.11.1 In-House Initiatives
8.4.11.2. Recent Regulatory Approvals of Repurposed Drugs
8.5. Other Big Pharma Players
8.5.1. Initiatives Undertaken by Pfizer
8.5.1.1. Initiatives in Collaboration with Other Stakeholders
9. CASE STUDY: DISCONTINUED DRUG DEVELOPMENT PROGRAMS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Drug Repurposing: Discontinued Clinical Trials
9.3.1. Analysis by Trial Status
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.3.4. Analysis by Therapeutic Area
9.3.5. Analysis by Location of Trial Site
9.3.6. Analysis by Phase Distribution versus Cause of Discontinuation of Clinical Research
9.3.7. Analysis by Trial Phase and Key Therapeutic Area
9.3.8. Analysis by Cause of Discontinuation of Clinical Research and Key Therapeutic Area
9.4. Discontinued Clinical Trials: Key Therapeutic Area
9.4.1. Discontinued Clinical Trials: Oncology Disorders
9.4.1.1. Analysis by Trial Status
9.4.1.2. Analysis by Trial Status
9.4.1.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.1.4. Analysis by Location of Trial Site
9.4.2. Discontinued Clinical Trials: CNS Disorders
9.4.2.1. Analysis by Trial Status
9.4.2.2. Analysis by Trial Status
9.4.2.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.2.4. Analysis by Location of Trial Site
9.4.3. Discontinued Clinical Trials: Metabolic Disorders
9.4.3.1. Analysis by Trial Status
9.4.3.2. Analysis by Trial Status
9.4.3.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.3.4. Analysis by Location of Trial Site
9.4.4. Discontinued Clinical Trials: Infectious Disorders
9.4.4.1. Analysis by Trial Status
9.4.4.2. Analysis by Trial Phase
9.4.4.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.4.4. Analysis by Location of Trial Site
9.4.5. Discontinued Clinical Trials: Autoimmune Disorders
9.4.5.1. Analysis by Trial Status
9.4.5.2. Analysis by Trial Phase
9.4.5.3. Analysis by Cause of Discontinuation of Clinical Research
9.4.5.4. Analysis by Location of Trial Site
9.5. List of Potential Drug Candidates
10. COST SAVING ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions
10.3. Methodology
10.4. Overall Cost Saving Potential of Repurposed Drugs, 2020-2030
10.5. Concluding Remarks
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Overall Drug Repurposing Services Market, 2020-2030
11.4. Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020-2030
11.4.1. Drug Repurposing Services Market for Small Molecules, 2020-2030
11.4.2. Drug Repurposing Services Market for Biologics, 2020-2030
11.5. Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020-2030
11.5.1. Drug Repurposing Services Market for Same Therapeutic Area, 2020-2030
11.5.2. Drug Repurposing Services Market for Different Therapeutic Area, 2020-2030
11.6. Drug Repurposing Services Market: Distribution by Company Size, 2020-2030
11.6.1. Drug Repurposing Services Market for Small Companies, 2020-2030
11.6.2. Drug Repurposing Services Market for Mid-Sized Companies, 2020-2030
11.6.3. Drug Repurposing Services Market for Large and Very Large Companies, 2020-2030
11.7. Drug Repurposing Services Market: Distribution by Geography, 2020, 2025 and 2030
11.7.1. Drug Repurposing Services Market in North America, 2020-2030
11.7.2. Drug Repurposing Services Market in Europe, 2020-2030
11.7.3. Drug Repurposing Services Market in Asia Pacific, 2020-2030
12. COVID-19 IMPACT ON DRUG REPURPOSING SERVICE PROVIDERS MARKET
12.1. Chapter Overview
12.2. Current opinions and recuperative initiatives of key players
12.2.1. Biovista
12.2.2. Evotec
12.2.3. Excelra
12.2.4. GVK Bio
12.3. Recuperative strategies for service providers businesses
12.3.1. Strategies for implementation in the short / mid term
12.3.2. Strategies for implementation in the long term
13. RECENT ADVANCEMENTS AND TRENDS IN OUTSOURCING OF DRUG REPURPOSING
13.1. Chapter Overview
13.2. Shift from One-Time Contracts to Strategic Partnerships
13.3. Adoption of New and Innovative Technologies
13.3.1. Artificial Intelligence
13.3.2. Next Generation Drug Repurposing Techniques
13.4. Focus on Niche Therapeutic Areas
13.5. Increase in Financial Inflow and Outsourcing Budgets
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Nandu Gattu (Senior Vice President, Excelra)
15. APPENDIX 1: LIST OF POTENTIAL DRUG-INDICATION CANDIDATES FOR DRUG REPURPOSING
16. APPENDIX 2: TABULATED DATA
17. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 History of Drug Repurposing
Figure 3.2 Different Types of Computational Methods Used for Drug Repurposing
Figure 3.3 Schematic Representation of Traditional versus Repurposing Approaches for Drug Discovery
Figure 3.4Benefits of Drug Repurposing
Figure 3.5 Challenges Associated with Drug Repurposing
Figure 3.6 Types of Drug Repurposing Service Providers
Figure 4.1Drug Repurposing Service Providers: Distribution by Type of Company
Figure 4.2Drug Repurposing Service Providers: Distribution by Type of Company, Year of Establishment and Location of Headquarters
Figure 4.3 Drug Repurposing CROs: Distribution by Year of Establishment
Figure 4.4 Drug Repurposing CROs: Distribution by Company Size
Figure 4.5 Drug Repurposing CROs: Distribution by Location of Headquarters
Figure 4.6 Drug Repurposing CROs: Distribution by Company Size and Location of Headquarters
Figure 4.7Drug Repurposing CROs: Distribution by Technology Specifications
Figure 4.8 Drug Repurposing CROs: Distribution by Type of Drug Molecule
Figure 4.9 Drug Repurposing CROs: Distribution by Status of Drug
Figure 4.10 Drug Repurposing CROs: Distribution by Repurposing Approach
Figure 4.11 Drug Repurposing CROs: Distribution by Types of Services Offered
Figure 4.12 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Company Size
Figure 4.13 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Location of Headquarters
Figure 4.14 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.15 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Technology Specifications
Figure 4.16 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Type of Drug Molecule
Figure 4.17 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Status of Drug
Figure 4.18 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Repurposing Approach
Figure 4.19 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Types of Services Offered
Figure 4.20 Drug Repurposing Technology Providers: Distribution by Year of Establishment
Figure 4.21 Drug Repurposing Technology Providers: Distribution by Company Size
Figure 4.22 Drug Repurposing Technology Providers: Distribution by Location of Headquarters
Figure 4.23 Drug Repurposing Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 4.24 Drug Repurposing Technology Providers: Distribution by Technology Specifications
Figure 4.25 Drug Repurposing Technology Providers: Distribution by Type of Drug Molecule
Figure 4.26 Drug Repurposing Technology Providers: Distribution by Status of Drug
Figure 4.27 Drug Repurposing Technology Providers: Distribution by Repurposing Approach
Figure 4.28 Drug Repurposing Technology Providers: Distribution by Types of Services Offered
Figure 6.1Auxiliis Pharma: Service Portfolio
Figure 6.2ChemBio Discovery Solutions: Service Portfolio
Figure 6.3 GVK Bio: Service Portfolio
Figure 6.4 Iris Pharma: Service Portfolio
Figure 6.5 Physiogenex: Service Portfolio
Figure 6.6 Excelra: Service Portfolio
Figure 6.7 Smart Pharma: Service Portfolio
Figure 6.8 Lantern Pharma: Service Portfolio
Figure 6.9 Panxome: Service Portfolio
Figure 6.10 Pharmacelera: Service Portfolio
Figure 6.11 Socium: Service Portfolio
Figure 6.12 SOM Biotech: Service Portfolio
Figure 7.1 Drug Repurposing Service Providers: Cumulative Distribution by Year of Partnership, Pre-2015-2020
Figure 7.2 Drug Repurposing Service Providers: Distribution by Type of Partnership
Figure 7.3 Drug Repurposing Service Providers: Distribution by Year and Type of Partnership
Figure 7.4 Drug Repurposing Service Providers: Distribution by Type of Technology / Platform Used
Figure 7.5 Drug Repurposing Service Providers: Distribution by Therapeutic Area
Figure 7.6 Drug Repurposing Service Providers: Continent-wise Distribution
Figure 7.7 Drug Repurposing Service Providers: Country-wise Distribution
Figure 8.1 Big Pharma Players: Distribution by Number of Drug Repurposing Initiatives, 2011-2020
Figure 8.2Big Pharma Players: Cumulative Distribution by Year of Initiative
Figure 8.3Big Pharma Players: Distribution by Type of Initiative
Figure 8.4Big Pharma Players: Distribution by Therapeutic Area
Figure 8.5Big Pharma Players: Distribution by Type of Drug Molecule
Figure 8.6Big Pharma Activity: Distribution by Year of Initiative and Company
Figure 8.7Big Pharma Activity: Distribution by Type of Drug Molecule and Company
Figure 8.8Big Pharma Investment Summary
Figure 9.1Discontinued Clinical Trials: Distribution by Trial Status
Figure 9.2Discontinued Clinical Trials: Distribution by Trial Phase
Figure 9.3Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research
Figure 9.4Discontinued Clinical Trials: Distribution by Therapeutic Area
Figure 9.5Discontinued Clinical Trials: Distribution by Location of Trial Site
Figure 9.6Discontinued Clinical Trials: Distribution by Phase versus Cause of Discontinuation of Clinical Research
Figure 9.7 Discontinued Clinical Trials: Distribution by Trial Phase and Key Therapeutic Area
Figure 9.8 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research and Key Therapeutic Area
Figure 9.9 Discontinued Clinical Trials: Distribution by Trial Status for Oncology Disorders
Figure 9.10 Discontinued Clinical Trials: Distribution by Trial Phase for Oncology Disorders
Figure 9.11 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Oncology Disorders  
Figure 9.12 Discontinued Clinical Trials: Distribution by Location of Trial Site for Oncology Disorders
Figure 9.13 Discontinued Clinical Trials: Distribution by Trial Status for CNS Disorders
Figure 9.14 Discontinued Clinical Trials: Distribution by Trial Phase for CNS Disorders
Figure 9.15 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for CNS Disorders
Figure 9.16 Discontinued Clinical Trials: Distribution by Location of Trial Site for CNS Disorders
Figure 9.17 Discontinued Clinical Trials: Distribution by Trial Status for Metabolic Disorders
Figure 9.18 Discontinued Clinical Trials: Distribution by Trial Phase for Metabolic Disorders
Figure 9.19 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Metabolic Disorders
Figure 9.20 Discontinued Clinical Trials: Distribution by Location of Trial Site for Metabolic Disorders
Figure 9.21 Discontinued Clinical Trials: Distribution by Trial Status for Infectious Disorders
Figure 9.22 Discontinued Clinical Trials: Distribution by Trial Phase for Infectious Disorders
Figure 9.23 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Infectious Disorders
Figure 9.24 Discontinued Clinical Trials: Distribution by Location of Trial Site for Infectious Disorders
Figure 9.25 Discontinued Clinical Trials: Distribution by Trial Status for Autoimmune Disorders
Figure 9.26 Discontinued Clinical Trials: Distribution by Trial Phase for Autoimmune Disorders
Figure 9.27 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Autoimmune Disorders
Figure 9.28 Discontinued Clinical Trials: Distribution by Location of Trial Site for Autoimmune Disorders
Figure 10.1 Overall Cost Saving Potential of Repurposed Drugs, 2020-2030 (USD Billion)
Figure 11.1 Overall Drug Repurposing Services Market, Base Scenario, 2020-2030 (USD Million)
Figure 11.2 Drug Repurposing Services Market: Distribution by Type of Drug Molecule, Base Scenario, 2020-2030 (%)
Figure 11.3 Drug Repurposing Services Market for Small Molecules, Base Scenario, 2020-2030 (USD Million)
Figure 11.4 Drug Repurposing Services Market for Biologics, Base Scenario, 2020-2030 (USD Million)
Figure 11.5 Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030 (%)
Figure 11.6 Drug Repurposing Services Market for Same Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Figure 11.7 Drug Repurposing Services Market for Different Therapeutic Area, Base Scenario, 2020-2030 (USD Million)
Figure 11.8 Drug Repurposing Services Market: Distribution by Company Size, Base Scenario, 2020-2030 (%)
Figure 11.9 Drug Repurposing Services Market for Small Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.10 Drug Repurposing Outsourcing Market for Mid-Sized Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.11 Drug Repurposing Outsourcing Market for Large and Very Large Companies, Base Scenario, 2020-2030 (USD Million)
Figure 11.12 Drug Repurposing Outsourcing Market: Distribution by Geography, 2020, 2025 and 2030 (%)
Figure 11.13 Drug Repurposing Outsourcing Market in North America, Base Scenario, 2020-2030 (USD Million)
Figure 11.14 Drug Repurposing Outsourcing Market in Europe, Base Scenario, 2020-2030 (USD Million)
Figure 11.15 Drug Repurposing Outsourcing Market in Asia Pacific, Base Scenario, 2020-2030 (USD Million)
LIST OF TABLES
Table 4.1 Drug Repurposing Service Providers: List of CROs
Table 4.2 Drug Repurposing Service Providers: List of Big Data / Analytics Service Providers
Table 4.3 Drug Repurposing Service Providers: List of Technology Providers
Table 4.4 Drug Repurposing Service Providers: Information related to Type of Drug Molecule
Table 5.1 Drug Repurposing Service Providers: List of Non-Profit Organizations
Table 5.2 Cures Within Reach: Organization Overview
Table 5.3 GlobalCures: Organization Overview
Table 5.4 Anticancer Fund: Organization Overview
Table 5.5 NCATS: Organization Overview
Table 5.6 Drug Repurposing Service Providers: List of Academic Organizations
Table 6.1 Auxiliis Pharma: Company Overview
Table 6.2 ChemBio Discovery Solutions: Company Overview
Table 6.3 GVK Bio: Company Overview
Table 6.4 GVK Bio: Future Outlook
Table 6.5 Iris Pharma: Company Overview
Table 6.6 Physiogenex: Company Overview
Table 6.7 Excelra: Company Overview
Table 6.8 Excelra: Future Outlook
Table 6.9 Smart Pharma: Company Overview
Table 6.10 Lantern Pharma: Company Overview
Table 6.11 Panxome: Company Overview
Table 6.12 Pharmacelera: Company Overview
Table 6.13 Socium: Company Overview
Table 6.14 SOM Biotech: Company Overview
Table 6.15 SOM Biotech: Future Outlook
Table 7.1 Drug Repurposing Service Providers: List of Partnerships, 2013-2020
Table 7.2 Drug Repurposing Service Providers: Information on Type of Technology / Platform and Therapeutic Area
Table 8.1 List of Drug Repurposing Initiatives of Big Pharma Players
Table 8.2 AbbVie: In-House Initiatives
Table 8.3 Astellas Pharma: Initiatives in Collaboration with Other Stakeholders
Table 8.4 Astellas Pharma: Recent Regulatory Approvals of Repurposed Drugs
Table 8.5 AstraZeneca: In-House Initiatives
Table 8.6 AstraZeneca: Initiatives in Collaboration with Other Stakeholders
Table 8.7 Bayer: Initiatives in Collaboration with Other Stakeholders
Table 8.8 Boehringer Ingelheim: Initiatives in Collaboration with Other Stakeholders
Table 8.9 Boehringer Ingelheim: Recent Regulatory Approvals of Repurposed Drugs
Table 8.10 Eli Lilly: Initiatives in Collaboration with Other Stakeholders
Table 8.11 Eli Lilly: Recent Regulatory Approvals of Repurposed Drugs
Table 8.12 Gilead Sciences: Recent Regulatory Approvals of Repurposed Drugs
Table 8.13 GSK: In-House Initiatives
Table 8.14 GSK: Initiatives in Collaboration with Other Stakeholders
Table 8.15 Novartis: In-House Initiatives
Table 8.16 Novartis: Initiatives in Collaboration with Other Stakeholders
Table 8.17 Novartis: Recent Regulatory Approvals of Repurposed Drugs
Table 8.18 Roche: In-House Initiatives
Table 8.19 Roche: Initiatives in Collaboration with Other Stakeholders
Table 8.20 Sanofi: In-House Initiatives
Table 8.21 Sanofi: Recent Regulatory Approvals of Repurposed Drugs
Table 8.22 Pfizer: Initiatives in Collaboration with Other Stakeholders
Table 9.1 List of Potential Drug Candidates
Table 10.1 Likely Cost Reduction for Repurposed Drugs
Table 15.1 Overall List of Potential Drug-Indication Candidates
Table 15.2 List of Potential Drug-Indication Candidates for Oncology Disorders
Table 15.3 List of Potential Drug-Indication Candidates for CNS Disorders
Table 15.4 List of Potential Drug-Indication Candidates for Metabolic Disorders
Table 15.5 List of Potential Drug-Indication Candidates for Infectious Disorders
Table 15.6 List of Potential Drug-Indication Candidates for Autoimmune Disorders
Table 17.1 Drug Repurposing Service Providers: Distribution by Company Type
Table 17.2 Drug Repurposing Service Providers: Distribution by Company Type, Year of Establishment and Location of Headquarters
Table 17.3 Drug Repurposing CROs: Distribution by Year of Establishment
Table 17.4 Drug Repurposing CROs: Distribution by Company Size
Table 17.5 Drug Repurposing CROs: Distribution by Location of Headquarters
Table 17.6 Drug Repurposing CROs: Distribution by Company Size and Location of Headquarters
Table 17.7 Drug Repurposing CROs: Distribution by Technology Specifications
Table 17.8 Drug Repurposing CROs: Distribution by Type of Drug Molecule
Table 17.9 Drug Repurposing CROs: Distribution by Status of Drug
Table 17.10 Drug Repurposing CROs: Distribution by Repurposing Approach
Table 17.11 Drug Repurposing CROs: Distribution by Type of Services Offered
Table 17.12 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Year of Establishment
Table 17.13 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Company Size
Table 17.14 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Location of Headquarters
Table 17.15 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Company Size and Location of Headquarters
Table 17.16 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Technology Specifications
Table 17.17 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Type of Drug Molecule
Table 17.18 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Status of Drug
Table 17.19 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Repurposing Approach
Table 17.20 Drug Repurposing Big Data / Analytics Service Providers: Distribution by Type of Services Offered
Table 17.21 Drug Repurposing Technology Providers: Distribution by Year of Establishment
Table 17.22 Drug Repurposing Technology Providers: Distribution by Company Size
Table 17.23 Drug Repurposing Technology Providers: Distribution by Location of Headquarters
Table 17.24 Drug Repurposing Technology Providers: Distribution by Company Size and Location of Headquarters
Table 17.25 Drug Repurposing Technology Providers: Distribution by Technology Specifications
Table 17.26 Drug Repurposing Technology Providers: Distribution by Type of Drug Molecule
Table 17.27 Drug Repurposing Technology Providers: Distribution by Status of Drug
Table 17.28 Drug Repurposing Technology Providers: Distribution by Repurposing Approach
Table 17.29 Drug Repurposing Technology Providers: Distribution by Type of Services Offered
Table 17.30 Drug Repurposing Service Providers: Cumulative Distribution by Year of Partnership Pre-2015-2020
Table 17.31 Drug Repurposing Service Providers: Distribution by Type of Partnership
Table 17.32 Drug Repurposing Service Providers: Distribution by Type of Technology / Platform Used
Table 17.33 Drug Repurposing Service Providers: Distribution by Therapeutic Area
Table 17.34 Drug Repurposing Service Providers: Country-wise Distribution
Table 17.35 Big Pharma Players: Distribution by Number of Drug Repurposing Initiatives, 2011-2020
Table 17.36 Big Pharma Players: Cumulative Distribution by Year of Initiative
Table 17.37 Big Pharma Players: Distribution by Type of Initiative
Table 17.38 Big Pharma Players: Distribution by Therapeutic Area
Table 17.39 Big Pharma Players: Distribution by Type of Drug Molecule
Table 17.40 Discontinued Clinical Trials: Distribution by Trial Status
Table 17.41 Discontinued Clinical Trials: Distribution by Trial Phase
Table 17.42 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research
Table 17.43 Discontinued Clinical Trials: Distribution by Therapeutic Area
Table 17.44 Discontinued Clinical Trials: Distribution by Location of Trial Site
Table 17.45 Discontinued Clinical Trials: Distribution by Phase versus Cause of Discontinuation of Clinical Research
Table 17.46 Discontinued Clinical Trials: Distribution by Trial Status for Oncology Disorders
Table 17.47 Discontinued Clinical Trials: Distribution by Trial Phase for Oncology Disorders
Table 17.48 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Oncology Disorders  
Table 17.49 Discontinued Clinical Trials: Distribution by Location of Trial Site for Oncology Disorders
Table 17.50 Discontinued Clinical Trials: Distribution by Trial Status for CNS Disorders
Table 17.51 Discontinued Clinical Trials: Distribution by Trial Phase for CNS Disorders
Table 17.52 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for CNS Disorders
Table 17.53 Discontinued Clinical Trials: Distribution by Location of Trial Site for CNS Disorders
Table 17.54 Discontinued Clinical Trials: Distribution by Trial Status for Metabolic Disorders
Table 17.55 Discontinued Clinical Trials: Distribution by Trial Phase for Metabolic Disorders
Table 17.56 Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Metabolic Disorders
Table 17.57 Discontinued Clinical Trials: Distribution by Location of Trial Site for Metabolic Disorders
Table 17.58Discontinued Clinical Trials: Distribution by Trial Status for Infectious Disorders
Table 17.59Discontinued Clinical Trials: Distribution by Trial Phase for Infectious Disorders
Table 17.60Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Infectious Disorders
Table 17.61Discontinued Clinical Trials: Distribution by Location of Trial Site for Infectious Disorders
Table 17.62Discontinued Clinical Trials: Distribution by Trial Status for Autoimmune Disorders
Table 17.63Discontinued Clinical Trials: Distribution by Trial Phase for Autoimmune Disorders
Table 17.64Discontinued Clinical Trials: Distribution by Cause of Discontinuation of Clinical Research for Autoimmune Disorders
Table 17.65Discontinued Clinical Trials: Distribution by Location of Trial Site for Autoimmune Disorders
Table 17.66Overall Cost Saving Potential of Repurposed Drugs, 2020-2030 (USD Billion)
Table 17.67 Overall Drug Repurposing Services Market, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.68 Drug Repurposing Services Market: Distribution by Type of Drug Molecule, 2020-2030 (%)
Table 17.69 Drug Repurposing Services Market for Small Molecules, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.70 Drug Repurposing Services Market for Biologics, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.71 Drug Repurposing Services Market: Distribution by Therapeutic Area, 2020, 2025 and 2030 (%)
Table 17.72 Drug Repurposing Services Market for Same Therapeutic Area, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.73 Drug Repurposing Services Market for Different Therapeutic Area, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.74 Drug Repurposing Services Market: Distribution by Company Size, 2020-2030
Table 17.75 Drug Repurposing Services Market for Small Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.76 Drug Repurposing Outsourcing Market for Mid-Sized Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.77 Drug Repurposing Outsourcing Market for Large and Very Large Companies, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.78 Drug Repurposing Outsourcing Market: Distribution by Geography, 2020, 2025 and 2030 (%)
Table 17.79 Drug Repurposing Outsourcing Market in North America, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.80 Drug Repurposing Outsourcing Market in Europe, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)
Table 17.81 Drug Repurposing Outsourcing Market in Asia Pacific, Base, Conservative, Optimistic Scenario, 2020-2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook